Filter articles using the following links

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

ARVO Annual Meeting, Honolulu, Hawaï, US

BioEurope Spring, Amsterdam, The Netherlands

44th NANOS, Hawaii, The Big Island, US

GenSight Biologics Reports Full Year 2017 Financial Results

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

Phacilitate Cell & Gene Therapy World, Miami, US

Oddo BHF Forum, Lyon, France